CDKN1B and pancreatic neoplasm: EHMT2 has been demonstrated to regulate also the expression of the CDK inhibitor p27KIP1 via the H3K9 mark, leading to an enhanced response to PI3K/mTOR inhibitors in pancreatic cancer cells resistant to gemcitabine [122].